Basic Information
| LncRNA/CircRNA Name | BISPR |
| Synonyms | lncBST2 |
| Region | GRCh38_19:17405686-17419324 |
| Ensemble | ENSG00000282851 |
| Refseq | NR_130765 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR, Western blot etc. |
| Sample | papillary thyroid cancer tissues, cell line (BHT101 and Hth83) |
| Expression Pattern | up-regulated |
| Function Description | BISPR in TPC tissues was over-expressed. BISPR knockdown restrained the propagation and invasiveness and enhanced the iodine uptake of TPC cells. The tumor-forming rate reduced after BISPR knockdown. In addition, miR-21-5p was lowly expressed in cancer tissues. BISPR promoted the development of TPC cells by inhibiting miR-21-5p expression. Bcl-2 was suppressed by miR-21-5p and sh-BISPR. BISPR, which was over-expressed in TPC, improved TPC cell viability, propagation, and invasiveness. MiR-21-5p was lowly expressed in TPC which inhibited Bcl-2 expression. BISPR stimulated propagation and invasiveness of TPC cells by depressing miR-21-5p. Patients with low expression of BISPR had higher fraction survival compared with patients with high BISPR expression. |
| Pubmed ID | 29856242 |
| Year | 2018 |
| Title | LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p. |
External Links
| Links for BISPR | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |